Jerri M. Rook

发表

Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release.

Jerri M. Rook, K. McCarson, J. M. Rook, 2007, Biochemical pharmacology.

Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships

Andrew S. Felts, Brian A. Chauder, K. Gregory, 2012, Molecular Pharmacology.

Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles

Andrew S. Felts, R. Kessler, C. Lindsley, 2015, Neuropsychopharmacology.

Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity

F. Dudek, K. Gregory, Z. Xiang, 2013, Biological Psychiatry.

Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines.

C. Lindsley, P. Conn, Alice L. Rodriguez, 2009, Journal of medicinal chemistry.

Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot

Kari A. Johnson, R. Kessler, R. Baldwin, 2011, Synapse.

Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Julie L. Engers, C. Lindsley, P. Conn, 2021, ACS medicinal chemistry letters.

Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.

J. Bartolomé-Nebreda, Carlos M Martínez-Viturro, G. Macdonald, 2015, Bioorganic & medicinal chemistry letters.

Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.

A. Megens, X. Langlois, J. Bartolomé-Nebreda, 2015, ACS medicinal chemistry letters.

Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism

Z. Xiang, C. Lindsley, P. Conn, 2013, Drug Metabolism and Disposition.

Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression.

W. Hasan, Jerri M. Rook, K. McCarson, 2009, Biochemical pharmacology.

Functional impact of allosteric agonist activity of selective positive allosteric modulators of mGlu 5 in regulating CNS function

H. Lavreysen, Z. Xiang, C. Lindsley, 2011 .

Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism

C. Lindsley, P. Conn, S. Deutsch, 2015, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.

Anna L. Blobaum, R. Blakely, C. Lindsley, 2016, Bioorganic & medicinal chemistry letters.

Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects

Andrew S. Felts, C. Lindsley, P. Conn, 2016, Neuropsychopharmacology.

Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation

D. Sheffler, Z. Xiang, C. Lindsley, 2017, Neuropsychopharmacology.

VU6010608, a Novel mGlu7 NAM from a Series of N-(2-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides.

Anna L. Blobaum, C. Lindsley, P. Conn, 2017, ACS medicinal chemistry letters.

Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.

S. P. Moran, Z. Xiang, C. Lindsley, 2017, ACS chemical neuroscience.

VU6010608, a Novel mGlu 7 NAM from a Series of N ‑ (2-(1 H ‑ 1,2,4-Triazol-1-yl)-5-(tri ﬂ uoromethoxy)phenyl)benzamides

Anna L. Blobaum, C. Lindsley, C. Niswender, 2017 .

Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics

Anna L. Blobaum, Z. Xiang, C. Lindsley, 2015, Journal of medicinal chemistry.

M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

S. P. Moran, Z. Xiang, C. Lindsley, 2018, Neuropsychopharmacology.

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

S. P. Moran, Anna L. Blobaum, C. Lindsley, 2018, ACS chemical neuroscience.

PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.

S. P. Moran, C. Lindsley, Hyekyung P. Cho, 2018, ACS chemical neuroscience.

Temporal Effects of Topical Morphine Application on Cutaneous Wound Healing

W. Hasan, Jerri M. Rook, K. McCarson, 2008, Anesthesiology.

Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).

K. Gregory, J. Meiler, Z. Xiang, 2013, Journal of medicinal chemistry.

Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity

P Jeffrey Conn, Craig W Lindsley, Colleen M Niswender, 2010, Molecular Pharmacology.

Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents

Kari A. Johnson, K. Gregory, J. Bartolomé-Nebreda, 2015, Neuron.

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

P. Conn, P. Conn, D. Choi, 2014, Neuropsychiatric disease and treatment.

Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function

H. Lavreysen, Z. Xiang, C. Lindsley, 2012, Molecular Pharmacology.

M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons

Z. Xiang, C. Lindsley, P. Conn, 2017, Neuropharmacology.

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction

Cody J. Wenthur, Z. Xiang, C. Lindsley, 2015, Proceedings of the National Academy of Sciences.

Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor

J. Wess, Z. Xiang, C. Lindsley, 2017, Neuron.

MECHANISMS OF CUTANEOUS WOUND HEALING ARE MEDIATED VIA PERIPHERAL NEUROPEPTIDE ACTIVITY

Jerri M. Rook, J. M. Rook, J. Rook, 2008 .

Allosteric modulation of metabotropic glutamate receptors

K. Gregory, D. Sheffler, P. Conn, 2013 .

mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome.

C. Lindsley, P. Conn, S. Stauffer, 2016, Human molecular genetics.

Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS chemical neuroscience.

Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release

M. J. Uddin, J. Wess, Z. Xiang, 2016, Neuron.